Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Margarita Reboredo Lopez"'
Autor:
Nieves Martínez-Lago, Teresa Calleja Chucla, Beatriz Alonso De Castro, Rafael Varela Ponte, Cristina Reboredo Rendo, Martin Igor Gomez-Randulfe Rodriguez, Sofia Silva Diaz, Begoña Graña Suarez, Juan de la Cámara Gomez, Fernando Busto Fernández, María Mateos Salvador, Margarita Reboredo Lopez
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract We evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC) in a retrospective, observational study. Patients refractory or intolerant to standard thera
Externí odkaz:
https://doaj.org/article/c57ed14ff76941199d651c58407ca464
Autor:
Nieves P. Martinez-Lago, Beatriz Alonso de Castro, Cristina Reboredo Rendo, Teresa Calleja, Martín Igor Gómez-Randulfe Rodríguez, Sofia Silva Diaz, Iria Parajó Vázquez, Maria Mateos Salvador, Fernando Busto Fernandez, Begona Grana Suarez, Juan De la camara, Margarita Reboredo Lopez
Publikováno v:
Journal of Clinical Oncology. 41:99-99
99 Background: TASBEV, compared with TAS-102, was associated with an improvement in progression-free survival (PFS) with tolerable toxicity in a randomized, open-label phase 2 trial. However, the subgroups of patients who may benefit from long-term T
Autor:
Mónica Jorge Fernández, Maria Luz Pellon Augusto, J. Méndez, Ana Montes, Juan de la Cámara Gómez, Mercedes Salgado Fernández, Margarita Reboredo Lopez, Nieves Martinez Lago, Guillermo Alfonso Quintero Aldana, Paula González Villaroel, Marta Covela Rúa, Jesús García Gómez, Begoña Graña Suárez
Publikováno v:
Cancer Medicine
Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI‐afliber
Autor:
Carlos Méndez Méndez, Begoña Graña Suárez, Sonia Candamio Folgar, Guillermo Alfonso Quintero Aldana, Paula Gonzalez Villarroel, Marta Covela Rúa, Elena Brozos Vazquez, Carlos Grande Ventura, Juan de la Cámara Gómez, Alberto Carral Maseda, Francisca Vázquez Rivera, Mercedes Salgado Fernández, Mónica Jorge Fernández, Marta Carmona Campos, Margarita Reboredo Lopez, Antia Cousillas Castiñeira, Ana Montes, Elena Gallardo Martin, Nieves Martinez Lago, Maria Luz Pellon Augusto
Publikováno v:
Journal of Clinical Oncology. 37:620-620
620 Background: Activating B-type Raf kinase (BRAF) mutations, mostly missense V600E, occur in approximately 8% to 12% of patients with metastatic colorectal cancer (mCRC). BRAF (V600E)mt is a strong predictor of a poor prognosis, with distinct clini
Autor:
Begoña Graña Suárez, Juan de la Cámara Gómez, Carlos Méndez Méndez, Elena Gallardo Martin, Nieves Martinez Lago, Maria Luz Pellon Augusto, Margarita Reboredo Lopez, Antia Cousillas Castiñeira, Sonia Candamio Folgar, Carlos Grande Ventura, Guillermo Alfonso Quintero Aldana, Paula Gonzalez Villarroel, Elena Brozos Vazquez, Mónica Jorge Fernández, Marta Covela Rúa, Ana Montes, Francisca Vázquez Rivera, Marta Carmona Campos, Mercedes Salgado Fernández, Alberto Carral Maseda
Publikováno v:
Journal of Clinical Oncology. 37:622-622
622 Background: Multiple studies have reported prognostic association of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLT) and albumin levels including patients with early and advanced metastatic colorectal cancer. However, it
Autor:
Mercedes Salgado Fernández, Antia Cousillas, Elena Brozos Vazquez, Mónica Jorge Fernández, Maria Luz Pellon Augusto, Begoña Graña, Ana Montes, Yolanda Vidal Insua, Paula Gonzalez Villarroel, Carlos Romero Reinoso, Marta Carmona Campos, Jose Carlos Mendez, Juan De la camara, Francisca Vázquez Rivera, Guillermo Alfonso Quintero Aldana, Sonia Candamio Folgar, Elena Gallardo Martin, Nieves Martinez Lago, Marta Covela Rúa, Margarita Reboredo Lopez
Publikováno v:
Journal of Clinical Oncology. 36:e15561-e15561
e15561Background: BRAF mutations, mostly missense V600E, occur in approximately 8% to 12% of patients with metastatic colorectal cancer (mCRC). BRAF (V600E) mt is a strong predictor of a poor progn...
Autor:
Nieves Martínez-Lago, Ana Fernández-Montes, Marta Covela, Elena M. Brozos, Juan De la Cámara, José C. Méndez Méndez, Mónica Jorge-Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo, David Arias Ron, María L. Pellón Augusto, Paula González Villarroel, Begoña Graña, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López, On behalf of the Galician Research Group on Digestive Tumors (GITuD)
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of
Externí odkaz:
https://doaj.org/article/0205a0ed5fdf486f96be2430c7159205